{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:40:01Z","timestamp":1772084401847,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1007\/bf03324509","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T23:49:31Z","timestamp":1374709771000},"page":"271-283","source":"Crossref","is-referenced-by-count":8,"title":["Injectable bisphosphonates in the treatment of postmenopausal osteoporosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Leonardo","family":"Sartori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Filipponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Crepaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,25]]},"reference":[{"key":"BF03324509_CR1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women. The OFELY study. J Bone Miner Res 2000; 15: 1526\u201336.","journal-title":"The OFELY study. J Bone Miner Res"},{"key":"BF03324509_CR2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478\u201387.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","volume":"83","author":"DE Hughes","year":"1989","unstructured":"Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83: 1930\u20135.","journal-title":"J Clin Invest"},{"key":"BF03324509_CR4","first-page":"2095","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effect on osteoclast ultra-structure. J Clin Invest 1991; 88: 2095\u2013105.","journal-title":"Alendronate localization in rat bone and effect on osteoclast ultra-structure. J Clin Invest"},{"key":"BF03324509_CR5","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/jbmr.5650091003","volume":"9","author":"RP Heaney","year":"1994","unstructured":"Heaney RP. The bone remodeling transient: Implication for the interpretation of clinical studies of bone mass changes. J Bone Miner Res 1994; 9: 1515\u201323.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/jc.79.6.1693","volume":"79","author":"P Garnero","year":"1994","unstructured":"Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas P. Comparison of new biochemical markers of bone turnover in postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693\u2013700.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03324509_CR7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C, Weil L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475\u201380.","journal-title":"J Clin Invest"},{"key":"BF03324509_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","volume":"15","author":"D Gatti","year":"1999","unstructured":"Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999; 15: 285\u201396.","journal-title":"Drugs Aging"},{"key":"BF03324509_CR9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"355","author":"PC Groen De","year":"1996","unstructured":"De Groen PC, Lubbe DF, Hirsh LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 355: 1016\u201321.","journal-title":"N Engl J Med"},{"key":"BF03324509_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging Clin Exp Res 2000; 12: 1\u201312.","journal-title":"Alendronate Once-Weekly Study Group. Aging Clin Exp Res"},{"key":"BF03324509_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4158\/EP.8.3.202","volume":"8","author":"MS Gordon","year":"2002","unstructured":"Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 2002; 8: 202\u20137.","journal-title":"Endocr Pract"},{"key":"BF03324509_CR12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(84)92272-4","volume":"1","author":"BF Boyce","year":"1984","unstructured":"Boyce BF, Fogelman I, Ralston S, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget\u2019s disease. Lancet 1984; 1: 821\u20134.","journal-title":"Lancet"},{"key":"BF03324509_CR13","first-page":"945","volume":"47","author":"GL Plosker","year":"1994","unstructured":"Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945\u201382.","journal-title":"A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs"},{"key":"BF03324509_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0221-8747(84)90012-2","volume":"5","author":"S Adami","year":"1984","unstructured":"Adami S, Guarrera G, Salvagno G, et al. Sequential treatment of Paget\u2019s disease with human calcitonin and dichloromethylene diphosphonate (C12MDP). Metab Bone Dis Relat Res 1984; 5: 265\u20137.","journal-title":"Metab Bone Dis Relat Res"},{"key":"BF03324509_CR15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S8756-3282(98)00133-1","volume":"23","author":"P Filipponi","year":"1998","unstructured":"Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget\u2019s disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone 1998; 23: 543\u20138.","journal-title":"Bone"},{"key":"BF03324509_CR16","first-page":"919","volume":"42","author":"H Fleisch","year":"1991","unstructured":"Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919\u201344.","journal-title":"Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs"},{"key":"BF03324509_CR17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0140-6736(90)90043-5","volume":"335","author":"JA Kanis","year":"1990","unstructured":"Kanis JA, McCloskey EV, Paterson AH. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet 1990; 335: 170\u20131.","journal-title":"Lancet"},{"key":"BF03324509_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0140-6736(93)90037-H","volume":"341","author":"HS Wasan","year":"1993","unstructured":"Wasan HS. Waxman J. Clodronate for multiple myeloma. Lancet 1993; 341: 175\u20136.","journal-title":"Clodronate for multiple myeloma. Lancet"},{"key":"BF03324509_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0029-7844(96)00171-8","volume":"88","author":"S Giannini","year":"1996","unstructured":"Giannini S, D\u2019Angelo A, Sartori L, Passeri G, Dalle Carbonare L, Crepaldi G. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol 1996; 88: 431\u20136.","journal-title":"Obstet Gynecol"},{"key":"BF03324509_CR20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S8756-3282(00)00437-3","volume":"28","author":"E McCloskey","year":"2001","unstructured":"McCloskey E, Selby P, de Takats D, et al. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 2001; 28: 310\u20135.","journal-title":"Bone"},{"key":"BF03324509_CR21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","volume":"10","author":"P Filipponi","year":"1995","unstructured":"Filipponi P, Pedetti M, Fedeli L, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995; 10: 697\u2013703.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1359\/jbmr.1997.12.1.103","volume":"12","author":"JE Heikkinen","year":"1997","unstructured":"Heikkinen JE, Seiander KS, Laitinen K, Arnala I, Vaananen HK. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 1997; 12: 103\u201310.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S8756-3282(99)00273-2","volume":"26","author":"P Filipponi","year":"2000","unstructured":"Filipponi P, Cristallini S, Policani G, Schifini MF, Casciari C, Garinei P. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone 2000; 26: 269\u201374.","journal-title":"Bone"},{"key":"BF03324509_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S8756-3282(98)00154-9","volume":"24","author":"M Rossini","year":"1999","unstructured":"Rossini M, Braga V, Gatti D, Gerardi D, Zamberlan N, Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone 1999; 24: 125\u20139.","journal-title":"Bone"},{"key":"BF03324509_CR25","first-page":"33","volume":"23","author":"S Gnudi","year":"2001","unstructured":"Gnudi S, Lisi L, Fini M, Malavolta N. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women. Int J Tissue React 2001; 23: 33\u20137.","journal-title":"Int J Tissue React"},{"key":"BF03324509_CR26","first-page":"289","volume":"41","author":"A Fitton","year":"1991","unstructured":"Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289\u2013318.","journal-title":"A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs"},{"key":"BF03324509_CR27","first-page":"CD003188","volume":"3","author":"B Djulbegovic","year":"2002","unstructured":"Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; 3: CD003188.","journal-title":"Cochrane Database Syst Rev"},{"key":"BF03324509_CR28","first-page":"3383","volume":"19","author":"R Hultbom","year":"1999","unstructured":"Hultbom R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 3383\u201392.","journal-title":"Anticancer Res"},{"key":"BF03324509_CR29","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III. double-blind, comparative trial. Cancer J 2001; 7: 377\u201387.","journal-title":"double-blind, comparative trial. Cancer J"},{"key":"BF03324509_CR30","first-page":"467","volume":"66","author":"A Trombetti","year":"1999","unstructured":"Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget\u2019s disease of bone. Rev Rheum Engl Ed 1999; 66: 467\u20136.","journal-title":"Rev Rheum Engl Ed"},{"key":"BF03324509_CR31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","volume":"18","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610\u20134.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","volume":"382","author":"JM Lane","year":"2001","unstructured":"Lane JM. Khan SN. O\u2019Connor WJ. et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 2001; 382: 6\u201312.","journal-title":"Clin Orthop"},{"key":"BF03324509_CR33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","volume":"17","author":"C Brumsen","year":"2002","unstructured":"Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057\u201364.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.79.6.1595","volume":"79","author":"IR Reid","year":"1994","unstructured":"Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate. in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595\u20139.","journal-title":"in postmenopausal osteoporosis. J Clin Endocrinol Metab"},{"key":"BF03324509_CR35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","volume":"4","author":"D Thiebaud","year":"1994","unstructured":"Thiebaud D, Burckhardt P, Melchior J, et al. Two years\u2019 effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4: 76\u201383.","journal-title":"Osteoporos Int"},{"issue":"Suppl1","key":"BF03324509_CR36","first-page":"S405","volume":"16","author":"SJ Wimalawansa","year":"2000","unstructured":"Wimalawansa SJ. Intermittent intravenous pamidronate therapy: highly effective treatment for postmenopausal osteoporosis. J Bone Miner Res 2000; 16(Suppl 1): S405 (Abstract).","journal-title":"J Bone Miner Res"},{"issue":"Suppl1","key":"BF03324509_CR37","first-page":"S35","volume":"8","author":"EV McCloskey","year":"1987","unstructured":"McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8(Suppl 1): S35\u201341.","journal-title":"Bone"},{"key":"BF03324509_CR38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.1994.176","volume":"69","author":"NP O\u2019Rourke","year":"1994","unstructured":"O\u2019Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994; 69: 914\u20137.","journal-title":"Br J Cancer"},{"key":"BF03324509_CR39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-9343(87)90699-1","volume":"83","author":"PD Delmas","year":"1987","unstructured":"Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget\u2019s disease of bone resistant to sodium etidronate. Am J Med 1987; 83: 276\u201382.","journal-title":"Am J Med"},{"key":"BF03324509_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S8756-3282(98)00133-1","volume":"23","author":"P Filipponi","year":"1998","unstructured":"Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget\u2019s disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone 1998; 23: 543\u20138.","journal-title":"Bone"},{"key":"BF03324509_CR41","first-page":"55","volume":"20","author":"S Adami","year":"2002","unstructured":"Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget\u2019s disease. Clin Exp Rheumatol 2002; 20: 55\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"BF03324509_CR42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18: 126\u201330.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/35.7.636","volume":"35","author":"JH Tobias","year":"1996","unstructured":"Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Br J Rheumatol 1996; 35: 636\u201341.","journal-title":"Br J Rheumatol"},{"key":"BF03324509_CR44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2000.15.3.599","volume":"15","author":"S Adami","year":"2000","unstructured":"Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000; 15: 599\u2013604.","journal-title":"J Bone Miner Res"},{"issue":"Suppl3","key":"BF03324509_CR45","first-page":"S31","volume":"30","author":"V Braga","year":"2002","unstructured":"Braga V, Gatti D, Bakri J, Fracassi E, Adami S. Intravenous cyclical neridronate in the treatment of postmenopausal osteoporosis. Bone 2002; 30(Suppl 3): S31 (Abstract).","journal-title":"Bone"},{"issue":"Suppl3","key":"BF03324509_CR46","first-page":"S48","volume":"30","author":"P Filipponi","year":"2002","unstructured":"Filipponi P, Cristallini S, Frediani B, Policani G, Schifini MF, Garinei P. Two years neridronate increases bone mineral density in postmenopausal women affected by osteoporosis. Bone 2002; 30(Suppl 3): S48 (Abstract).","journal-title":"Bone"},{"key":"BF03324509_CR47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199957010-00011","volume":"57","author":"M Dooley","year":"1999","unstructured":"Dooley M, Balfour JA. Ibandronate. Drugs 1999; 57: 101\u20138.","journal-title":"Drugs"},{"key":"BF03324509_CR48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","volume":"11","author":"M Pecherstorfer","year":"1996","unstructured":"Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996; 11: 587\u201393.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Pluijm van der","year":"1996","unstructured":"van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698\u2013705.","journal-title":"J Clin Invest"},{"key":"BF03324509_CR50","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","volume":"99","author":"T Yoneda","year":"1997","unstructured":"Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509\u201317.","journal-title":"J Clin Invest"},{"key":"BF03324509_CR51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/bjc.1997.48","volume":"75","author":"SH Ralston","year":"1997","unstructured":"Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75: 295\u2013300.","journal-title":"Br J Cancer"},{"key":"BF03324509_CR52","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20: 2353\u20139.","journal-title":"J Clin Oncol"},{"key":"BF03324509_CR53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clinchem\/46.5.684","volume":"46","author":"HW Woitge","year":"2000","unstructured":"Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R, Seibel MJ. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 2000; 46: 684\u201390.","journal-title":"Clin Chem"},{"key":"BF03324509_CR54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","volume":"19","author":"P Ravn","year":"1996","unstructured":"Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19: 527\u201333.","journal-title":"Bone"},{"key":"BF03324509_CR55","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","volume":"16","author":"BJ Riis","year":"2001","unstructured":"Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 1871\u20138.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"D Thiebaud","year":"1997","unstructured":"Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298\u2013307.","journal-title":"Am J Med"},{"issue":"Suppl1","key":"BF03324509_CR57","first-page":"S209","volume":"11","author":"RR Recker","year":"2000","unstructured":"Recker RR, Stakkestad JA, Felsenbers D, et al. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial. Osteoporos Int 2000; 11(Suppl 1): S209 (Abstract).","journal-title":"Osteoporos Int"},{"issue":"Suppl1","key":"BF03324509_CR58","first-page":"S472","volume":"17","author":"S Adami","year":"2002","unstructured":"Adami S, Christiansen C, Burdeska A, Coutant K, Mahoney P. Three-monthly 2 mg intravenous ibandronate injections restore bone turnover to premenopausal levels. J Bone Miner Res 2002; 17(Suppl 1): S472 (Abstract).","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR59","first-page":"77","volume":"3","author":"P Burckhardt","year":"2003","unstructured":"Burckhardt P, H\u00fcsi B, Thi\u00e9baud D, Jacquet A-F. Long term effect of a single dose of intravenous Ibandronate. J Musculoskel Neuron Interact 2003; 3: 77\u201382.","journal-title":"J Musculoskel Neuron Interact"},{"issue":"Suppl1","key":"BF03324509_CR60","first-page":"S17","volume":"13","author":"JA Stakkestad","year":"2002","unstructured":"Stakkestad JA, Skag A, Nordby A, Burdeska A, Jonkanski I, Meinert R. Three-monthly intravenous ibandronate bolus injections: A novel treatment regimen to prevent postmenopausal bone loss. Osteoporos Int 2002; 13(Suppl 1): S17 (Abstract).","journal-title":"Osteoporos Int"},{"key":"BF03324509_CR61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42446. a new. potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745\u201351.","journal-title":"a new. potent, heterocyclic bisphosphonate compound. J Bone Miner Res"},{"key":"BF03324509_CR62","first-page":"3721","volume":"45","author":"L Widler","year":"2002","unstructured":"Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45: 3721\u201338.","journal-title":"From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem"},{"key":"BF03324509_CR63","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191\u2013200.","journal-title":"Cancer"},{"key":"BF03324509_CR64","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III. double-blind, comparative trial. Cancer J 2001; 7: 377\u201387.","journal-title":"double-blind, comparative trial. Cancer J"},{"key":"BF03324509_CR65","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458\u201368.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl2","key":"BF03324509_CR66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(Suppl 2): 45\u201354.","journal-title":"Cancer Invest"},{"key":"BF03324509_CR67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/ard.62.3.275","volume":"62","author":"G Chung","year":"2003","unstructured":"Chung G. Keen RW. Zoledronate treatment in active Paget\u2019s disease. Ann Rheum Dis 2003; 62: 275\u20136.","journal-title":"Zoledronate treatment in active Paget\u2019s disease. Ann Rheum Dis"},{"key":"BF03324509_CR68","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653\u201361.","journal-title":"N Engl J Med"},{"key":"BF03324509_CR69","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326\u201331.","journal-title":"Calcif Tissue Int"},{"key":"BF03324509_CR70","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, L\u00f6wik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylaminohy-droxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956\u201362.","journal-title":"J Bone Miner Res"},{"key":"BF03324509_CR71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","volume":"15","author":"M Passeri","year":"1991","unstructured":"Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-l-hydroxybutilydene-l,l-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237\u201348.","journal-title":"Bone Miner"},{"key":"BF03324509_CR72","first-page":"227","volume":"143","author":"HM Frost","year":"1979","unstructured":"Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell population. Clin Orthop Rel Res 1979; 143: 227\u201344.","journal-title":"Clin Orthop Rel Res"},{"key":"BF03324509_CR73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02405341","volume":"36","author":"C Anderson","year":"1984","unstructured":"Anderson C, Cape RD, Crilly RG, et al. Preliminary observation of a form of coherence therapy for osteoporosis. Calcif Tissue Int 1984; 36: 341\u20133.","journal-title":"Calcif Tissue Int"},{"key":"BF03324509_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1115\/1.3168334","volume":"111","author":"CH Turner","year":"1989","unstructured":"Turner CH. Yield behaviour of cancellous bone. J Biomech Eng 1989; 111: 1\u20135.","journal-title":"J Biomech Eng"},{"key":"BF03324509_CR75","first-page":"736","volume":"338","author":"SR Cummings","year":"1995","unstructured":"Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 338: 736\u201346.","journal-title":"N Engl J Med"},{"key":"BF03324509_CR76","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedell H. Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254\u20139.","journal-title":"BMJ"},{"key":"BF03324509_CR77","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","volume":"42","author":"MC Hockberg","year":"1999","unstructured":"Hockberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246\u201354.","journal-title":"Arthritis Rheum"},{"key":"BF03324509_CR78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","volume":"85","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9041","key":"BF03324509_CR79","first-page":"1535","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535\u201341.","journal-title":"Fracture Intervention Trial Research Group. Lancet"},{"key":"BF03324509_CR80","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077\u201382.","journal-title":"JAMA"},{"key":"BF03324509_CR81","first-page":"83","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83\u201391.","journal-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int"},{"key":"BF03324509_CR82","first-page":"1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344\u201352.","journal-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA"},{"key":"BF03324509_CR83","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","volume":"312","author":"PLA Daele Van","year":"1996","unstructured":"Van Daele PLA, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482\u20133.","journal-title":"BMJ"},{"key":"BF03324509_CR84","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jc.80.12.3465","volume":"80","author":"JO Landman","year":"1995","unstructured":"Landman JO, Hamdy NAT, Pawels EKJ, et al. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab 1995; 80: 3465\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03324509_CR85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","volume":"103","author":"JL Stock","year":"1997","unstructured":"Stock JL, Bell NH, Chesnut CH III, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103: 291\u20137.","journal-title":"Am J Med"},{"key":"BF03324509_CR86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0773.1991.tb01312.x","volume":"69","author":"L Lauren","year":"1991","unstructured":"Lauren L, Osterman T, Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol 1991; 69: 365\u20138.","journal-title":"Pharmacol Toxicol"},{"key":"BF03324509_CR87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","volume":"14","author":"S Adami","year":"1996","unstructured":"Adami S. Zamberlan N. Adverse effects of bisphosphonates. Drug Safety 1996; 14: 158\u201360.","journal-title":"Adverse effects of bisphosphonates. Drug Safety"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03324509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03324509\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03324509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T16:58:57Z","timestamp":1596214737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03324509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["BF03324509"],"URL":"https:\/\/doi.org\/10.1007\/bf03324509","relation":{},"ISSN":["1594-0667","1720-8319"],"issn-type":[{"value":"1594-0667","type":"print"},{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}